Dabigatran

Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date

...y and safety of the oral direct thrombin inhibitor dabigatran etexilate with the current standard therapy, warfa...mbolism in patients with atrial fibrillation (AF). dabigatran etexilate is an oral anticoagulant in Phase III de...n AF, as well as several other therapeutic areas. dabigatran etexilate is not approved by the FDA. RE-LY(R) is...

Pill Equals Injection in Preventing Clots After Hip Replacement

...nce between the two protective treatments FRIDAY, Sept. 14 (HealthDay News) -- In a head-to-head trial, Swedish researchers found that a pill called dabigatran etexilate (DE) is just as effective as an injected drug, enoxaparin, in reducing the risk of blood clots after total hip replacement surgery. As re...

Dabigatran in Medical Technology

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

RIDGEFIELD, Conn., July 11, 2007 /PRNewswire/ -- Phase 3 results from the RE-NOVATE(TM) trial demonstrated that oral dabigatran etexilate once daily, administered for an average of 33 days, was non-inferior to enoxaparin, also administered for an average of 33 days, in preventing venous thromboemb...

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

... of investigational oral direct thrombin inhibitor dabigatran etexilate for the prevention of stroke and systemi...ive Phase III clinical trial program investigating dabigatran etexilate in more than 34,000 patients for the pre...r deaths (including deaths from bleeding). About dabigatran etexilate ...

The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor

... Study results outline dabigatran etexilate as potential thromboprophylaxis ther...sults from the RE-NOVATE study, which investigated dabigatran etexilate as a potential therapy for patients unde... and 150mg) of the oral direct thrombin inhibitor, dabigatran etexilate, administered for a median of 33 days, w...